J&J prostate cancer drug OK'd for wider use in EU

Published on NewsOK Modified: January 11, 2013 at 12:46 pm •  Published: January 11, 2013
Advertisement
;

"Treating men with Zytiga before they undergo chemotherapy has been shown to improve outcomes in many patients, both in terms of extending survival and in bettering quality of life," she said.

Zytiga, first approved in 2011, is on sale in more than 60 countries, including the U.S.

Cancer of the prostate, the gland surrounding the urethra that produces part of the seminal fluid, can progress so slowly that treatment isn't needed, or it can grow and spread to other body parts very quickly, depending on the individual patient and characteristics of his tumor.

Each year, prostate cancer kills roughly 90,000 men in Europe and about 28,000 in the U.S.

Shares of Johnson & Johnson rose 20 cents to $72.39 in afternoon trading Friday. They are near the high end of their 52-week range of $61.71 to $72.74.